BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26124180)

  • 1. High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis.
    Wang CY; Deng JY; Cai XW; Fu XL; Li Y; Zhou XY; Wu XH; Hu XC; Fan M; Xiang JQ; Zhang YW; Chen HQ; Perez R; Jiang GL; Zhao KL
    Oncotarget; 2015 Jul; 6(21):18674-82. PubMed ID: 26124180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.
    Jia J; Cui Y; Lu M; Wang X; Li J; Li J; Li Y; Zhang X; Gao J; Zhou J; Lu Z; Gong J; Yu J; Sun Z; Liu C; Shen L; Zhang X
    Clin Transl Oncol; 2016 Jun; 18(6):592-8. PubMed ID: 26459251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study.
    Rojo F; Gracias E; Villena N; Cruz T; Corominas JM; Corradino I; Cedeño M; Campas C; Osorio M; Iznaga N; Bellosillo B; Rovira A; Marsoni S; Gascon P; Serrano S; Sessa C; Crombet T; Albanell J
    Clin Cancer Res; 2010 Apr; 16(8):2474-82. PubMed ID: 20371675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorylated AKT1 is associated with poor prognosis in esophageal squamous cell carcinoma.
    Zhu Z; Yu W; Fu X; Sun M; Wei Q; Li D; Chen H; Xiang J; Li H; Zhang Y; Zhao W; Zhao K
    J Exp Clin Cancer Res; 2015 Sep; 34(1):95. PubMed ID: 26338103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined nimotuzumab with chemoradiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma: A retrospective study.
    Lai X; Gu Q; Zheng X; Liu G; Feng W; Lin X; Mao W
    J Cancer Res Ther; 2016 Oct; 12(Supplement):89-95. PubMed ID: 27721263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response.
    Javle M; Pande A; Iyer R; Yang G; LeVea C; Wilding G; Black J; Nava H; Nwogu C
    Am J Clin Oncol; 2008 Aug; 31(4):329-34. PubMed ID: 18845990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
    Jedlinski A; Ansell A; Johansson AC; Roberg K
    J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients.
    Reddy BK; Lokesh V; Vidyasagar MS; Shenoy K; Babu KG; Shenoy A; Naveen T; Joseph B; Bonanthaya R; Nanjundappa ; Bapsy PP; Loknatha ; Shetty J; Prasad K; Tanvir Pasha CR
    Oral Oncol; 2014 May; 50(5):498-505. PubMed ID: 24613543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3.
    Zhao L; He LR; Xi M; Cai MY; Shen JX; Li QQ; Liao YJ; Qian D; Feng ZZ; Zeng YX; Xie D; Liu MZ
    J Transl Med; 2012 Dec; 10():249. PubMed ID: 23232108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor.
    Zhang W; Pang Q; Zhang X; Yan C; Wang Q; Yang J; Yu S; Liu X; Pan Y; Yuan Z; Wang P; Xiao Z
    Cancer Sci; 2017 Apr; 108(4):590-597. PubMed ID: 28192623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of epidermal growth factor receptor overexpression with increased epidermal growth factor receptor gene copy number in esophageal squamous cell carcinomas.
    Yang YL; Xu KL; Zhou Y; Gao X; Chen LR
    Chin Med J (Engl); 2012 Feb; 125(3):450-4. PubMed ID: 22490401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients.
    Tzeng CW; Frolov A; Frolova N; Jhala NC; Howard JH; Vickers SM; Buchsbaum DJ; Heslin MJ; Arnoletti JP
    J Surg Res; 2007 Nov; 143(1):20-6. PubMed ID: 17950068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications.
    Bumrungthai S; Munjal K; Nandekar S; Cooper K; Ekalaksananan T; Pientong C; Evans MF
    J Transl Med; 2015 Jul; 13():244. PubMed ID: 26209091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DESC1, a novel tumor suppressor, sensitizes cells to apoptosis by downregulating the EGFR/AKT pathway in esophageal squamous cell carcinoma.
    Ng HY; Ko JM; Yu VZ; Ip JC; Dai W; Cal S; Lung ML
    Int J Cancer; 2016 Jun; 138(12):2940-51. PubMed ID: 26856390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.
    Janmaat ML; Gallegos-Ruiz MI; Rodriguez JA; Meijer GA; Vervenne WL; Richel DJ; Van Groeningen C; Giaccone G
    J Clin Oncol; 2006 Apr; 24(10):1612-9. PubMed ID: 16575012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
    Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
    J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Membranous expression of ectodomain isoforms of the epidermal growth factor receptor predicts outcome after chemoradiotherapy of lymph node-negative cervical cancer.
    Halle C; Lando M; Svendsrud DH; Clancy T; Holden M; Sundfør K; Kristensen GB; Holm R; Lyng H
    Clin Cancer Res; 2011 Aug; 17(16):5501-12. PubMed ID: 21737508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall Survival of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Nimotuzumab in the Real World.
    Saumell Y; Sanchez L; González S; Ortiz R; Medina E; Galán Y; Lage A
    Adv Ther; 2017 Dec; 34(12):2638-2647. PubMed ID: 29134427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Li SH; Huang EY; Lu HI; Huang WT; Yen CC; Huang WC; Chen CH
    J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1352-9, 1359.e1. PubMed ID: 22841170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas.
    Smilek P; Neuwirthova J; Jarkovsky J; Dusek L; Rottenberg J; Kostrica R; Srovnal J; Hajduch M; Drabek J; Klozar J
    Neoplasma; 2012; 59(5):508-15. PubMed ID: 22668015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.